S100a9 interaction screening method
AssigneeActive Biotech AB
InventorsPer Bjork, Fredrik Ivars, Tomas Leanderson
Life of this patent
Estimating the term…
Abstract
A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising: -determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or -determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.
Claims20
A method of identifying a compound for use in therapy which modulates the interaction of S100A9 with a ligand comprising:
- (i) determining whether a candidate compound is capable of modulating the interaction of S100A9 with RAGE or the interaction of S100A9 with a TLR (Toll like receptor), or
- (ii) determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S100A9 with RAGE or the binding of S100A9 with a TLR,
- to thereby identify whether the compound may be used in therapy, wherein optionally the method is carried out in the presence of calcium and zinc ions.
Dependencies are inferred from the claim text.